Published in final edited form as:

Drug Alcohol Depend. 2014 June 1; 139: 174–177. doi:10.1016/j.drugalcdep.2014.03.025.

Stimulant Use and HIV Disease Management Among Men in Same-Sex Relationships

Adam W. Carrico^{1,2}, Sarah E. Woolf-King², Torsten B. Neilands², Samantha E. Dilworth², and Mallory O. Johnson^{1,2,3}

¹University of California, San Francisco School of Nursing

²University of California, San Francisco Center for AIDS Prevention Studies (CAPS)

³University of California, San Francisco School of Pharmacy

Abstract

Background—Research conducted to date has focused primarily on identifying individual-level, psychological determinants of stimulant use and HIV disease management. The present cross-sectional study examined relationship factors as correlates of stimulant use and HIV disease management among men who have sex with men (MSM).

Methods—In total, 266 male couples completed a baseline assessment for a cohort study examining the role of relationship factors in HIV treatment. A computer-based assessment of relationship factors, self-reported alcohol and substance use, and self-reported anti-retroviral therapy (ART) adherence was administered. All HIV-positive participants also provided a blood sample to measure viral load.

Results—After controlling for demographic characteristics and relationship factors, men in a primary relationship with a stimulant-using partner had more than six-fold greater odds of reporting any stimulant use in the past three months. Among HIV-positive participants on ART ($n = 371$), having a stimulant-using partner was independently associated with 67% lower odds of reporting perfect 30-day ART adherence and more than two-fold greater odds of displaying a detectable HIV viral load. In contrast, more partner-level alcohol use was independently associated with greater odds of reporting perfect 3-day ART adherence and lower odds of displaying a detectable HIV viral load.

Conclusions—Partner-level stimulant use is an important risk factor for individual-level stimulant use and difficulties with HIV disease management among MSM. To optimize the

© 2014 Elsevier Ireland Ltd. All rights reserved.

Corresponding Author: Adam W. Carrico, University of California, San Francisco, School of Nursing, 2 Koret Way, N511M, San Francisco, CA 94143, Tel: 415-502-0955, Fax: 415-476-6042, adam.carrico@ucsf.edu.

Contributors: AWC, SWK, and MOJ developed the study hypotheses and analysis plan in collaboration with all other authors. SED and TBN were the primary individuals responsible for data analysis. Detailed comments on draft manuscripts prepared by AWC and SWK were provided by the entire team.

Conflict of Interest: No conflict declared

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

effectiveness of HIV treatment as prevention, clinical research is needed to develop couples-based interventions targeting stimulant use as a potential driver of detectable HIV viral load.

Keywords

Adherence; Cocaine; HIV; Methamphetamine; Treatment as Prevention; Viral Load

1. INTRODUCTION

Early initiation of anti-retroviral therapy (ART) optimizes health outcomes among HIV-positive persons (Cohen et al., 2011), and reductions in HIV viral load among those on ART decrease the likelihood of onward HIV transmission (Montaner et al., 2010). However, HIV-positive persons who use stimulants such as methamphetamine are at greater risk for experiencing difficulties with effectively managing ART regimens that contribute to elevated viral load and potentially faster disease progression (Carrico, 2011; Carrico et al., 2011; Ellis et al., 2003; Hinkin et al., 2007). Because stimulant users are also more likely to engage in HIV transmission risk behavior (Johnson et al., 2008; Morin et al., 2007; Parsons and Bimbi, 2007), higher HIV viral load may facilitate transmission of medication-resistant strains of HIV to uninfected sexual partners (Colfax et al., 2007; Gorbach et al., 2008; Mayer et al., 2013). Taken together, stimulant use has negative implications for both HIV prevention and care.

Social Control Theory has been applied to a range of health contexts (including same-sex male couples with HIV) to delineate the pathways whereby primary relationships may influence health behaviors (Johnson et al., 2012; Lewis and Butterfield, 2005; Lewis and Rook, 1999; Moos, 2007). Specifically, primary partners of individuals who engage in health risk behaviors are theorized to respond with positive or negative tactics to promote behavior change. The potential relevance of social control processes is supported by observations that marital functioning influences health behaviors in studies conducted with heterosexual couples (Kiecolt-Glaser and Newton, 2001). Among HIV-positive men who have sex with men (MSM), markers of greater relationship quality are also associated with better HIV disease management (Johnson et al., 2012). On the other hand, a substance-using primary partner has previously been identified as an important predictor of relapse in heroin users (Shah et al., 2006; Termorshuizen et al., 2005), which may be attributable to more permissive norms regarding heroin use and impaired social control. Informed by Social Control Theory, the goals of the present study with HIV-positive men in same-sex relationships were two-fold: (1) examine if partner-level stimulant use and indicators of poorer perceived relationship quality are associated with greater odds of stimulant use; and (2) determine whether partner-level stimulant use is independently associated with poorer ART adherence and detectable HIV viral load.

2. METHODS

Participants completed the baseline assessment for an interval cohort study examining the role of relationship factors in HIV treatment among HIV-positive men in same-sex relationships (Johnson et al., 2012). Inclusion criteria were as follows: (1) in a relationship for at least three months with someone to whom you feel committed above anyone else and

with whom you have had a sexual relationship (i.e., currently in a “primary” relationship); (2) both partners at least 18 years old, born male and currently identify as male; (3) at least one partner is HIV-positive and on an ART regimen for 30 days or more; (4) English speaking; and (5) able to provide informed consent.

2.1. Procedures

Self-report measures of relationship factors, alcohol and substance use, and ART adherence were completed using audio computer-assisted self-interviewing without the presence of the partner or interviewer. A peripheral venous blood sample was collected from HIV-positive participants. All procedures were approved by the Committee on Human Research at the University of California, San Francisco.

2.2. Measures

2.2.1. Demographics—Age, ethnicity, education, length of current relationship, couple HIV Status (i.e., seroconcordant HIV-positive or serodiscordant), time since HIV diagnosis, time since starting ART, and number of ART pills per day were assessed by questionnaire.

2.2.2. Relationship Factors—Several measures of relationship quality were administered. The 4-item Couples Satisfaction Index (Funk and Rogge, 2007) measured relationship satisfaction (Partner: $M = 15.0$, $SD = 4.3$). Adapted scales from Kurdek (1995) assessed relationship commitment (Partner: $M = 32.5$, $SD = 5.7$), autonomy (Actor: $M = 33.2$, $SD = 8.7$), and intimacy (Actor: $M = 37.7$, $SD = 9.0$). Finally, relationship communication was assessed with a 5-item constructive communication subscale (Christensen and Shenk, 1991; Actor: $M = 33.5$, $SD = 7.6$). All relationship factors displayed adequate internal consistency (i.e., Cronbach’s α range: 0.74–0.93).

2.2.3. Alcohol Use Disorders Identification Test (AUDIT)—The AUDIT is a validated 10-item measure that screens for hazardous alcohol consumption and alcohol use disorders (Saunders et al., 1993).

2.2.4. Stimulant Use—Participants provided separate ratings of how often they used powder cocaine, crack, or methamphetamine in the past three months. Responses ranged from 0 (not at all) to 7 (daily). Participants who reported any stimulant use (1) were compared to those reported no stimulant use (0).

2.2.5. ART Adherence—ART adherence was assessed using two self-report measures. The AIDS Clinical Trials Group (ACTG) measure provides the percentage of ART medications taken over the prior three days (Chesney et al., 2000). The visual analog scale (VAS) measures the proportion of ART medications taken in the past 30 days by asking participants to place an “x” along a line ranging from 0% to 100% (Walsh et al., 2002). Because self-report measures often overestimate ART adherence (Simoni et al., 2006), we chose to compare those who reported 100% ART adherence (1) to participants who reported less than 100% adherence (0).

2.2.6. HIV Viral Load—HIV viral load testing was performed to detect HIV RNA at or above 50 copies/ml (Roche Molecular Systems, Inc.).

2.3. Statistical Analyses

Actor-partner models comprise a dyadic analysis method used to examine the mutual influence that members of dyads have on each other's outcomes (Kenny et al., 2006). To examine correlates of any stimulant use in the past three months, each participant's perceived relationship factors were included as predictors of his own stimulant use (i.e., actor effects). In addition, the stimulant use and perceived relationship factors of the primary partner were included as predictors the actor's stimulant use (i.e., partner effects).

Any stimulant use and all significant relationship factors from our prior research (Johnson et al., 2012) were included for actors and partners in models examining correlates of ART adherence and HIV viral load. Because alcohol use has been consistently associated with poorer ART adherence (Hendershot et al., 2009), the AUDIT scores for the actor and partner were also included as predictors. A HIV-positive partner may also have more opportunities to model behaviors that optimize HIV disease management. Consequently, couple HIV status was examined as a moderator of the associations of actor and partner stimulant use with indices of HIV disease management. Estimation of actor-partner regression models was performed via generalized estimating equations (GEE), with an exchangeable correlation structure and robust standard errors to properly account for correlated outcomes for partners who are members of the same couple. Finally, we examined whether the associations of actor and partner stimulant use with indices of HIV disease management were mediated by relationship factors. The user-written command KHB in Stata 12 was employed to test the significance of indirect effects to determine if mediation was present (Kohler et al., 2011). For all analyses, missing data were minimal (<5%) and listwise deletion was employed.

3. RESULTS

3.1. Demographics

Most of the 532 participants were HIV-positive (78%), Caucasian (56%), middle-aged ($M = 45.8$, $SD = 10.4$) gay or bisexual (98%) men. Participants had been in their current primary relationship for 6.6 ($SD = 6.8$) years on average and most were in HIV-positive seroconcordant relationships (56%). More than one in four participants (29%) reported any stimulant use in the past three months. HIV-positive participants ($N = 414$) had been diagnosed for 13.4 ($SD = 8.0$) years and had been taking ART for 9.6 ($SD = 7.0$) years on average. Most HIV-positive participants were currently prescribed ART (91%). Those on ART were taking a median of three ART pills per day and 50% had a detectable HIV viral load.

3.2. Correlates of Any Stimulant Use

As shown in Table 1, having a stimulant-using partner was independently associated with more than 6-fold greater odds of reporting any stimulant use in the past three months (Adjusted Odds Ratio [AOR] = 6.47, 95% CI = 3.44 – 12.17, $p < .0001$).

3.3. Correlates of ART Adherence and HIV Viral Load

As shown in Table 2, HIV-positive seroconcordant couples had close to seven times the odds of perfect 3-day ART adherence relative to HIV serodiscordant couples, when the partner reported stimulant use (AOR = 6.87; 95% CI = 1.83, 25.73; $p < .01$). In addition, having a stimulant-using partner was independently associated with lower odds of reporting perfect 30-day ART adherence (AOR = 0.33, 95% CI = 0.15 – 0.72; $p < 0.01$) and more than two-fold greater odds of displaying a detectable HIV viral load (AOR = 2.32, 95% CI = 1.42 – 3.80; $p < 0.01$). On the other hand, a higher partner AUDIT score was independently associated with greater odds of reporting perfect 3-day ART adherence (AOR = 1.18, 95% CI = 1.06 – 1.31, $p < .01$) and lower odds of displaying detectable HIV viral load (AOR = 0.94, 95% CI = 0.90 – 0.98, $p < .01$). Mediation analyses indicated that the indirect effects of partner-level stimulant use on ART adherence and detectable viral load via relationship factors were not statistically significant.

4. DISCUSSION

Consistent with adapted Social Control Theory (Lewis and Rook, 1999), the present study observed that having a stimulant-using partner was independently associated with substantially greater odds of engaging in stimulant use. This may be because a stimulant-using partner is less likely to implement social control processes to promote reductions in a risk behavior that is perceived to be normative. Bearing in mind that MSM often use stimulants for sexual enhancement (Green and Halkitis, 2006), a stimulant-using primary partner may also serve as a trigger for using stimulants together as a couple. Although relationship factors were not significantly associated with stimulant use in this study, further research is needed to examine the role of permissive partner norms regarding stimulant use as well as positive and negative tactics implemented to decrease stimulant use among male couples. This could inform efforts to adapt couples-based, substance abuse treatments such as behavioral couples therapy for stimulant-using male couples (O'Farrell and Fals-Stewart, 2000).

This study also is among the first to observe that partner-level stimulant use is independently associated with poorer HIV disease management. It is noteworthy, however, that the associations of partner-level stimulant use with poorer ART adherence and detectable HIV viral load were not mediated by relationship factors. Future longitudinal research should examine if lower concordance of perceived relationship quality, disruption of daily routines, food insecurity, and intimate partner violence mediate the deleterious effects of partner-level stimulant use on poorer HIV disease management (Horvath et al., 2013; Johnson et al., 2012; Pantalone et al., 2010; Weiser et al., 2009). There was also some indication that having a HIV-positive partner buffered against the negative association of partner-level stimulant use with poorer ART adherence. This may be because a HIV-positive primary partner has more opportunities to model behaviors that support ART adherence as a form of positive social control (Lewis and Butterfield, 2005; Lewis and Rook, 1999). This study also replicated prior research with this sample where higher partner-level alcohol use was independently associated with *greater* odds of reporting perfect 3-day ART adherence and *lower* odds of displaying a detectable HIV viral load (Woolf-King et al., 2013). Longitudinal

research is needed to determine if discrepant couple-level patterns of stimulant and alcohol use differentially predict difficulties with HIV disease management.

Findings from this study should be interpreted in context of some important limitations. First, stimulant use was assessed using self-report measures that did not adequately characterize patterns of use, route(s) of administration, or screen for the presence of a stimulant use disorder. Future studies should include more comprehensive assessments of stimulant use and polysubstance use. Second, longitudinal research is needed to determine whether and how partner-level stimulant use may serve as a risk factor for ongoing stimulant use as well as difficulties with HIV disease management. Despite these limitations, findings from this study highlight that interventions targeting stimulant-using male couples could optimize the effectiveness of HIV treatment as prevention.

Acknowledgments

Role of Funding Source: This research was supported by the National Institute of Nursing Research (R01-NR010187; Johnson, PI) and the National Institute of Mental Health (K24-MH087220; Johnson, PI).

References

- Carrico AW. Substance use and HIV disease progression in the HAART era: implications for the primary prevention of HIV. *Life Sci.* 2011; 88:940–947.10.1016/j.lfs.2010.10.002 [PubMed: 20934437]
- Carrico AW, Riley ED, Johnson MO, Charlebois ED, Neilands TB, Remien RH, Lightfoot MA, Steward WT, Weinhardt LS, Kelly JA, Rotheram-Borus MJ, Morin SF, Chesney MA. Psychiatric risk factors for HIV disease progression: the role of inconsistent patterns of antiretroviral therapy utilization. *J Acquir Immune Defic Syndr.* 2011; 56:146–150.10.1097/QAI.0b013e318201df63 [PubMed: 21116186]
- Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instruments. *AIDS Care.* 2000; 12:255–266.10.1080/09540120050042891 [PubMed: 10928201]
- Christensen A, Shenk JL. Communication, conflict, and psychological distance in nondistressed, clinic, and divorcing Couples. *J Consult Clin Psychol.* 1991; 59:458–463.10.1037/0022-006x.59.3.458 [PubMed: 2071731]
- Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med.* 2011; 365:493–505.10.1056/NEJMoa1105243 [PubMed: 21767103]
- Colfax GN, Vittinghoff E, Grant R, Lum P, Spotts G, Hecht FM. Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance. *AIDS.* 2007; 21:239–241.10.1097/QAD.0b013e3280114a29 [PubMed: 17197817]
- Ellis RJ, Childers ME, Cherner M, Lazzaretto D, Letendre S, Grant I. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. *J Infect Dis.* 2003; 188:1820–1826. JID30762 [pii]. 10.1086/379894 [PubMed: 14673760]
- Funk JL, Rogge RD. Testing the ruler with item response theory: increasing precision of measurement for relationship satisfaction with the Couples Satisfaction Index. *J Fam Psychol.* 2007; 21:572–583.10.1037/0893-3200.21.4.572 [PubMed: 18179329]

- Gorbach PM, Drumright LN, Javanbakht M, Pond SL, Woelk CH, Daar ES, Little SJ. Antiretroviral drug resistance and risk behavior among recently HIV-infected men who have sex with men. *J Acquir Immune Defic Syndr*. 2008; 47:639–643.10.1097/QAI.0b013e3181684c3d [PubMed: 18285715]
- Green AI, Halkitis PN. Crystal methamphetamine and sexual sociality in an urban gay subculture: an elective affinity. *Cult Health Sex*. 2006; 8:317–333.10.1080/13691050600783320 [PubMed: 16846941]
- Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis. *J Acquir Immune Defic Syndr*. 2009; 52:180–202. [PubMed: 19668086]
- Hinkin CH, Barclay TR, Castellon SA, Levine AJ, Durvasula RS, Marion SD, Myers HF, Longshore D. Drug use and medication adherence among HIV-1 infected individuals. *AIDS Behav*. 2007; 11:185–194.10.1007/s10461-006-9152-0 [PubMed: 16897351]
- Horvath KJ, Carrico AW, Simoni J, Boyer EW, Amico KR, Petroll AE. Engagement in HIV medical care and technology use among stimulant-using and nonstimulant-using men who have sex with men. *AIDS Res Treat*. 2013 Epub ahead of print. 10.1155/2013/121352
- Johnson MO, Carrico AW, Chesney MA, Morin SF. Internalized heterosexism among HIV-positive, gay-identified men: implications for HIV prevention and care. *J Consult Clin Psychol*. 2008; 76:829–839.10.1037/0022-006X.76.5.829 [PubMed: 18837600]
- Johnson MO, Dilworth SE, Taylor JM, Darbes LA, Comfort ML, Neilands TB. Primary relationships, HIV treatment adherence, and virologic control. *AIDS Behav*. 2012; 16:1511–1521.10.1007/s10461-011-0021-0 [PubMed: 21811842]
- Kenny, DA.; Kashy, DA.; Cook, WL. *Dyadic Data Analysis*. Guilford Press; New York: 2006. p. 144
- Kiecolt-Glaser JK, Newton TL. Marriage and health: his and hers. *Psychol Bull*. 2001; 127:472–503. [PubMed: 11439708]
- Kohler U, Karlson K, Holm A. Comparing coefficients of nested nonlinear probability models. *STATA J*. 2011; 11:420–438.
- Kurdek LA. Assessing multiple determinants of relationship commitment in cohabiting gay, cohabiting lesbian, dating heterosexual, and married heterosexual couples. *Fam Relat*. 1995; 44:261–266.10.2307/585524
- Lewis MA, Butterfield RM. Antecedents and reactions to health-related social control. *Person Soc Psychol Bull*. 2005; 31:416–427.
- Lewis MA, Rook KS. Social control in personal relationships: Impact on health behaviors and psychological distress. *Health Psychol*. 1999; 18:63–71. [PubMed: 9925047]
- Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, Shannon K, Harrigan PR, Hogg RS, Daly P, Kendall P. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. *Lancet*. 2010; 376:532–539.10.1016/S0140-6736(10)60936-1 [PubMed: 20638713]
- Mayer KH, Skeer MR, O'Cleirigh C, Goshe BM, Safren SA. Factors associated with amplified HIV transmission behavior among American men who have sex with men engaged in care: implications for clinical providers. *Ann Behav Med*. 2013:1–7.
- Moos RH. Theory-based active ingredients of effective treatments for substance use disorders. *Drug Alcohol Depend*. 2007; 88:109–121. [PubMed: 17129682]
- Morin SF, Myers JJ, Shade SB, Koester K, Maiorana A, Rose CD. Predicting HIV transmission risk among HIV-infected patients seen in clinical settings. *AIDS Behav*. 2007; 11(5 Suppl):S6–16.10.1007/s10461-007-9253-4 [PubMed: 17577655]
- O'Farrell TJ, Fals-Stewart W. Behavioral couples therapy for alcoholism and drug abuse. *J Subst Abuse Treat*. 2000; 18:51–54. [PubMed: 10636606]
- Pantalone DW, Hessler DM, Simoni JM. Mental health pathways from interpersonal violence to health-related outcomes in HIV-positive sexual minority men. *J Consult Clin Psychol*. 2010; 78:387–397.10.1037/a0019307 [PubMed: 20515213]
- Parsons JT, Bimbi DS. Intentional unprotected anal intercourse among sex who have sex with men: barebacking - from behavior to identity. *AIDS Behav*. 2007; 11:277–287.10.1007/s10461-006-9135-1 [PubMed: 16775771]

- Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. *Addiction*. 1993; 88:791–804. [PubMed: 8329970]
- Shah NG, Galai N, Celentano DD, Vlahov D, Strathdee SA. Longitudinal predictors of injection cessation and subsequent relapse among a cohort of injection drug users in Baltimore, MD, 1988–2000. *Drug Alcohol Depend*. 2006; 83:147–156.10.1016/j.drugalcdep.2005.11.007 [PubMed: 16364568]
- Simoes AA, Bastos FI, Moreira RI, Lynch KG, Metzger DS. A randomized trial of audio computer and in-person interview to assess HIV risk among drug and alcohol users in Rio De Janeiro, Brazil. *J Subst Abuse Treat*. 2006; 30:237–243.10.1016/j.jsat.2005.12.002 [PubMed: 16616168]
- Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. *AIDS Behav*. 2006; 10:227–245.10.1007/s10461-006-9078-6 [PubMed: 16783535]
- Termorshuizen F, Krol A, Prins M, Geskus R, van den Brink W, van Ameijden EJ. Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. *Drug Alcohol Depend*. 2005; 79:231–240.10.1016/j.drugalcdep.2005.01.013 [PubMed: 16002032]
- Walsh JC, Pozniak AL, Nelson MR, Mandalia S, Gazzard BG. Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. *J Acquir Immune Defic Syndr*. 2002; 30:278–287.10.1097/01.Qai.0000018000.56638.43 [PubMed: 12131564]
- Weiser SD, Bangsberg DR, Kegeles S, Ragland K, Kushel MB, Frongillo EA. Food insecurity among homeless and marginally housed individuals living with HIV/AIDS in San Francisco. *AIDS Behav*. 2009; 13:841–848. [PubMed: 19644748]
- Woolf-King SE, Neilands TB, Dilworth SE, Carrico AW, Johnson MO. Alcohol use and HIV disease management: the impact of individual and partner-level alcohol use among HIV-positive men who have sex with men. *AIDS Care*. 2013; 26:702–708. [PubMed: 24215238]

Table 1

Correlates of any self-reported stimulant use in the past three months (N = 532)

	AOR (95% CI)
Age	0.97 (0.95, 0.99) *
HIV-Positive	1.11 (0.50, 2.51)
Concordant HIV-positive status	1.01 (0.59, 1.72)
Race/Ethnicity	—
White	—
Black	0.75 (0.39, 1.42)
Latino	0.71 (0.38, 1.34)
Other	1.44 (0.75, 2.76)
College graduate or greater	1.00 (0.62, 1.63)
Income	1.00 (0.92, 1.09)
Years in current primary relationship	0.98 (0.94, 1.01)
Actor's relationship factors	
Satisfaction	0.98 (0.90, 1.06)
Commitment	0.97 (0.92, 1.02)
Autonomy	0.99 (0.97, 1.02)
Intimacy	1.03 (1.00, 1.06)
Communication	0.97 (0.93, 1.00)
Partner's relationship factors	
Satisfaction	1.01 (0.92, 1.11)
Commitment	0.97 (0.93, 1.03)
Autonomy	0.99 (0.96, 1.01)
Intimacy	1.01 (0.98, 1.04)
Communication	1.01 (0.97, 1.04)
Any partner stimulant use (past 3 months)	6.47 (3.44, 12.17) **

*
p < .05;**
p < .01

Table 2

Correlates of self-reported ART adherence and HIV viral load (N = 371).

	Perfect ACTG 3-Day Adherence	Perfect VAS 30-Day Adherence	Detectable Viral Load
	AOR (95% CI)	AOR (95% CI)	AOR (95% CI)
Relationship length (years)	0.97 (0.92, 1.03)	1.01 (0.97, 1.05)	0.95 (0.92, 0.99)*
Concordant HIV-positive status	2.76 (1.27, 5.96)**	1.46 (0.80, 2.67)	1.48 (0.91, 2.39)
Actor			
Years on ART	0.99 (0.95, 1.04)	0.92 (0.88, 0.96)**	1.01 (0.98, 1.05)
Autonomy	1.00 (0.96, 1.04)	1.02 (0.99, 1.05)	1.00 (0.97, 1.03)
Intimacy	1.01 (0.97, 1.05)	1.01 (0.98, 1.05)	1.03 (1.00, 1.06)
Communication	0.98 (0.92, 1.05)	1.01 (0.97, 1.05)	0.99 (0.96, 1.02)
AUDIT	0.96 (0.90, 1.02)	0.92 (0.85, 0.98)**	1.04 (1.00, 1.08)
Any Stimulant Use	0.48 (0.22, 1.05)	0.53 (0.26, 1.06)	1.19 (0.75, 1.89)
Partner			
Satisfaction	1.01 (0.92, 1.12)	1.00 (0.91, 1.09)	0.98 (0.91, 1.05)
Commitment	1.03 (0.96, 1.10)	1.03 (0.96, 1.11)	0.99 (0.95, 1.04)
AUDIT	1.18 (1.06, 1.31)**	1.05 (1.00, 1.10)	0.94 (0.90, 0.98)**
Any Stimulant Use	1.05 (0.45, 2.46)	0.33 (0.15, 0.72)**	2.32 (1.42, 3.80)**
Concordant HIV+/Any Stimulant Use	6.87 (1.83, 25.73)** †	—	—
HIV Discordant/Any Stimulant Use	1.11 (0.47, 2.59) †	—	—

ART: Anti-Retroviral Therapy; AUDIT: Alcohol Use Disorders Identification Test

AOR = adjusted odds ratio; CI = confidence interval;

*
p < .05,**
p < .01;†
the interaction of couple HIV status and partner's stimulant use is significant at p=.03 in the 3-day adherence model.